{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:00:26Z","timestamp":1784311226275,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6\u2009months. Patient follow-up was performed in specialised severe asthma units.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3\u2009months of treatment compared with baseline (13.9\u2009\u00b1\u20094 vs 20.1\u2009\u00b1\u20093.7,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and at 6\u2009months of treatment compared with the results obtained at 3\u2009months (20.1\u2009\u00b1\u20093.7 vs 21\u2009\u00b1\u20092.7,<jats:italic>p<\/jats:italic>\u2009=\u20090.037). Similarly, the number of emergency department visits decreased both at 3\u2009months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75],<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and at 6\u2009months compared with the results at 3\u2009months (0 [IR:0.75] vs 0 [IR:0],<jats:italic>p<\/jats:italic>\u2009=\u20090.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291\u2009mL (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and FEV1% improved both at 3\u2009months compared with baseline (64.4\u2009\u00b1\u20099.3 vs 73.1\u2009\u00b1\u20099.1,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and at 6\u2009months compared to 3\u2009months (73.1\u2009\u00b1\u20099.1 vs 76.1\u2009\u00b1\u200912,<jats:italic>p<\/jats:italic>\u2009=\u20090.002). Side effects were mild and did not lead to treatment discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6\u2009months of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12890-020-01220-9","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T13:03:52Z","timestamp":1593435832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Real-life experience with benralizumab during 6 months"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-2716","authenticated-orcid":false,"given":"A.","family":"Padilla-Galo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RCh","family":"Levy-Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Valencia Azcona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rez Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rivas-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tortajada-Goitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Moya-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Levy-Naon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"1220_CR1","unstructured":"Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), 2019. http:\/\/www.ginasthma.org\/."},{"issue":"2","key":"1220_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1398-9995.2006.01305.x","volume":"62","author":"J Bousquet","year":"2007","unstructured":"Bousquet J, Clark TJH, Hurd S, Khaltaev N, Lenfant C, O'byrne P, et al. GINA guidelines on asthma and beyond. Allergy. 2007;62(2):102\u201312.","journal-title":"Allergy."},{"key":"1220_CR3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"issue":"5","key":"1220_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","volume":"59","author":"M Masoli","year":"2004","unstructured":"Masoli M, Fabian D, Holt S, Beasley R. Global initiative for asthma (GINA) program: the global burden of asthma: executive summary of the GINA dissemination committee report. Allergy. 2004;59(5):469\u201378.","journal-title":"Allergy."},{"key":"1220_CR5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09059180.00002110","volume":"19","author":"P Demoly","year":"2010","unstructured":"Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev. 2010;19:150\u20137.","journal-title":"Eur Respir Rev"},{"issue":"7","key":"1220_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.arbres.2010.01.007","volume":"46","author":"FJ Gonz\u00e1lez Barcala","year":"2010","unstructured":"Gonz\u00e1lez Barcala FJ, de la Fuente-Cid R, Alvarez-Gil R, Tafalla M, Nuevo J, Caama\u00f1o-Isorna F. Factors associated with asthma control in primary care patients: the CHAS study. Arch Bronconeumol. 2010;46(7):358\u201363.","journal-title":"Arch Bronconeumol"},{"key":"1220_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PP Hekking","year":"2015","unstructured":"Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896\u2013902.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1220_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/20734735.008914","volume":"11","author":"ML Levy","year":"2015","unstructured":"Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe (Sheff). 2015;11(1):14\u201324.","journal-title":"Breathe (Sheff)"},{"issue":"7","key":"1220_CR9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.rmed.2006.03.031","volume":"100","author":"SP Peters","year":"2006","unstructured":"Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139\u201351.","journal-title":"Respir Med"},{"key":"1220_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13223-018-0241-1","volume":"14","author":"D Husereau","year":"2018","unstructured":"Husereau D, Goodfield J, Leigh R, Borrelli R, Cloutier M, Gendron A. Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy Asthma Clin Immunol. 2018;14:15.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"1220_CR11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/02770903.2018.1452034","volume":"56","author":"D Eassey","year":"2019","unstructured":"Eassey D, Reddel HK, Foster JM, Kirkpatrick S, Locock L, Ryan K, et al. \"\u2026 I've said I wish I was dead, you'd be better off without me\": a systematic review of people's experiences of living with severe asthma. J Asthma. 2019;56(3):311\u201322.","journal-title":"J Asthma"},{"issue":"12","key":"1220_CR12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1080\/02770903.2018.1539100","volume":"56","author":"K Al Efraij","year":"2019","unstructured":"Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, FitzGerald JM. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma. 2019;56(12):1334\u201346.","journal-title":"J Asthma"},{"key":"1220_CR13","doi-asserted-by":"publisher","unstructured":"Casan Clar\u00e0 P, Mart\u00ednez GC. Accumulated dose of systemic corticosteroids: significant medical information. Arch Bronconeumol. 2020;S0300-2896(20):30032\u20136. https:\/\/doi.org\/10.1016\/j.arbres.2020.01.007. Epub ahead of print.","DOI":"10.1016\/j.arbres.2020.01.007"},{"key":"1220_CR14","unstructured":"Xolair (Omalizumab). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xolair."},{"key":"1220_CR15","first-page":"321","volume":"5","author":"G Gnanakumaran","year":"2003","unstructured":"Gnanakumaran G, Babu KS. Technology evaluation: mepolizumab. GlaxoSmithKline Curr Opin Mol Therapeut. 2003;5:321\u20135.","journal-title":"GlaxoSmithKline Curr Opin Mol Therapeut"},{"key":"1220_CR16","first-page":"7","volume":"7","author":"GM Walsh","year":"2013","unstructured":"Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics. 2013;7:7\u201311.","journal-title":"Biologics."},{"key":"1220_CR17","volume-title":"AstraZeneca pharmaceuticals LP","author":"Fasenra [US prescribing information]","year":"2017","unstructured":"Fasenra [US prescribing information]. AstraZeneca pharmaceuticals LP; 2017."},{"issue":"2","key":"1220_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","volume":"29","author":"I D\u00e1vila Gonz\u00e1lez","year":"2019","unstructured":"D\u00e1vila Gonz\u00e1lez I, Moreno Ben\u00edtez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29(2):84\u201393.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"1220_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.arbres.2019.03.024","volume":"56","author":"P Casan Clar\u00e0","year":"2020","unstructured":"Casan Clar\u00e0 P, Mart\u00ednez GC. Biologics in the treatment of asthma. Arch Bronconeumol. 2020;56(3):137\u20138.","journal-title":"Arch Bronconeumol"},{"key":"1220_CR20","doi-asserted-by":"publisher","unstructured":"Cataldo D, Louis R, Michils A, Pech\u00e9 R, Pilette C, Schleich F, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2020:1\u201311. https:\/\/doi.org\/10.1080\/02770903.2019.1705335. Epub ahead of print.","DOI":"10.1080\/02770903.2019.1705335"},{"key":"1220_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2019.03.006","volume":"151","author":"L P\u00e9rez de Llano","year":"2019","unstructured":"P\u00e9rez de Llano L, Mart\u00ednez-Morag\u00f3n E, Plaza Moral V, Trisan Alonso A, Almonacid S\u00e1nchez C, Callejas FJ, et al. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. Respir Med. 2019;151:49\u201354.","journal-title":"Respir Med"},{"issue":"8","key":"1220_CR22","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.jaip.2019.05.053","volume":"7","author":"P Comberiati","year":"2019","unstructured":"Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for Mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689\u201396.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1220_CR23","doi-asserted-by":"crossref","unstructured":"Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015:879783.","DOI":"10.1155\/2015\/879783"},{"key":"1220_CR24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","volume":"197","author":"TF Carr","year":"2018","unstructured":"Carr TF, Zeki AA, Kraft M. Eosinophilic and non-eosinophilic asthma. Am J Respir Crit Care Med. 2018;197:22\u201337.","journal-title":"Am J Respir Crit Care Med"},{"key":"1220_CR25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3838","volume":"12","author":"PC Fulkerson","year":"2013","unstructured":"Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12:117\u201329.","journal-title":"Nat Rev Drug Discov"},{"key":"1220_CR26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","volume":"180","author":"PG Woodruff","year":"2009","unstructured":"Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. Thelper type 2-driven inflammation defines major sub-phenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"1220_CR27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(00)00690-7","volume":"406","author":"X Zhang","year":"2000","unstructured":"Zhang X, Moilanen CE, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000;406:325\u201332.","journal-title":"Eur J Pharmacol"},{"key":"1220_CR28","doi-asserted-by":"crossref","unstructured":"de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1).","DOI":"10.1183\/23120541.00024-2015"},{"key":"1220_CR29","doi-asserted-by":"publisher","unstructured":"Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia GE. Ability of serum IgE concentration to predict exacerbation risk and Benralizumab efficacy for patients with severe eosinophilic asthma. Adv Ther. 2019. https:\/\/doi.org\/10.1007\/s12325-019-01191-2.","DOI":"10.1007\/s12325-019-01191-2"},{"key":"1220_CR30","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327.","journal-title":"Lancet."},{"key":"1220_CR31","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128\u201341.","journal-title":"Lancet."},{"key":"1220_CR32","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448\u201358.","journal-title":"N Engl J Med"},{"key":"1220_CR33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46\u201359.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1220_CR34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12931-018-0746-7","volume":"19","author":"A Padilla-Galo","year":"2018","unstructured":"Padilla-Galo A, Olveira C, Fern\u00e1ndez de Rota-Garcia L, Marco-Galve I, Plata AJ, Alvarez A, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res. 2018;19(1):43.","journal-title":"Respir Res"},{"issue":"1","key":"1220_CR35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/02770903.2018.1426766","volume":"56","author":"JC Fernandes","year":"2019","unstructured":"Fernandes JC, Biskupiak WW, Brokaw SM, Carpenedo D, Loveland KM, Tysk S, et al. Outcomes of the Montana asthma home visiting program: a home-based asthma education program. J Asthma. 2019;56(1):104\u201310.","journal-title":"J Asthma"},{"issue":"10","key":"1220_CR36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.arbres.2019.01.014","volume":"55","author":"C Rodr\u00edguez-Garc\u00eda","year":"2019","unstructured":"Rodr\u00edguez-Garc\u00eda C, Lourido-Cebreiro T, Gonz\u00e1lez-Barcala FJ. The ATAUD study: the need to improve adherence. Arch Bronconeumol. 2019;55(10):509\u201310.","journal-title":"Arch Bronconeumol"},{"issue":"7","key":"1220_CR37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thx.54.7.581","volume":"54","author":"JC Bestall","year":"1999","unstructured":"Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581\u20136.","journal-title":"Thorax."},{"key":"1220_CR38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Natham","year":"2004","unstructured":"Natham RA, Sorkness Ch A, Kosinski M, Schatz M, Li J, Marcus PH. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"1220_CR39","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/02770900701752615","volume":"44","author":"JM Vega","year":"2007","unstructured":"Vega JM, Badia X, Badiola C, L\u00f3pez-Vi\u00f1a A, Olagu\u00edbel JM, Picado C. Validation of the Spanish version of the asthma control test (ACT). J Asthma. 2007;44:867\u201372.","journal-title":"J Asthma"},{"issue":"8","key":"1220_CR40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. Am J Respir Crit Care Med. 2005;171(8):912\u201330.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1220_CR41","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1164\/ajrccm\/136.5.1285","volume":"136","author":"Standardization of spirometry","year":"1987","unstructured":"Standardization of spirometry. Statement of the American thoracic society. Am Rev Respir Dis. 1987;136(5):1285\u201398.","journal-title":"Am Rev Respir Dis"},{"key":"1220_CR42","unstructured":"R statistical: Department of Statistics, University of Auckland, Auckland, NZ; http:\/\/www.r-project.org\/."},{"issue":"10","key":"1220_CR43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jclinepi.2009.07.013","volume":"63","author":"N Freemantle","year":"2010","unstructured":"Freemantle N, Strack T. Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. J Clin Epidemiol. 2010;63(10):1053\u20138.","journal-title":"J Clin Epidemiol"},{"key":"1220_CR44","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.pupt.2019.101830","volume":"58","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Busceti MT, Vatrella A, Rago GF, Crimi C, Terracciano R, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830.","journal-title":"Pulm Pharmacol Ther"},{"key":"1220_CR45","doi-asserted-by":"crossref","unstructured":"Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE trial. ERJ Open Res. 2019;5(3).","DOI":"10.1183\/23120541.00009-2019"},{"issue":"4","key":"1220_CR46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.arbres.2017.10.018","volume":"54","author":"P Casan","year":"2018","unstructured":"Casan P, Fern\u00e1ndez Tena A, Mart\u00ednez C. More Platon and less Prozac: the arrival of ASTHMA-ZUMAB. Arch Bronconeumol. 2018;54(4):181\u20132.","journal-title":"Arch Bronconeumol"},{"key":"1220_CR47","doi-asserted-by":"crossref","unstructured":"Arismendi E, Picado VC. Current role of biomarkers in severe uncontrolled asthma. Arch Bronconeumol. 2019.","DOI":"10.1016\/j.arbr.2019.08.016"},{"issue":"9","key":"1220_CR48","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","volume":"71","author":"A Magnan","year":"2016","unstructured":"Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335\u201344.","journal-title":"Allergy."},{"issue":"9","key":"1220_CR49","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","volume":"74","author":"KR Chapman","year":"2019","unstructured":"Chapman KR, Albers FC, Chipps B, Mu\u00f1oz X, Devouassoux G, Bergna M, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716\u201326.","journal-title":"Allergy."},{"issue":"7","key":"1220_CR50","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jaip.2019.01.017","volume":"7","author":"LA P\u00e9rez de Llano","year":"2019","unstructured":"P\u00e9rez de Llano LA, Cos\u00edo BG, Domingo C, Urrutia I, Bobolea I, Valero A, et al. Efficacy and safety of Reslizumab in patients with severe asthma with inadequate response to Omalizumab: a multicenter, open-label pilot study. J Allergy Clin Immunol Pract. 2019;7(7):2277\u201383.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1220_CR51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","volume":"120","author":"BE Chipps","year":"2018","unstructured":"Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120:504\u201311.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01220-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01220-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01220-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T20:16:16Z","timestamp":1667160976000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01220-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01220-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all participants. The study was reviewed by the Spanish Medicines and Health Products Agency and approved by the ethics committee <i>Comit\u00e9 de \u00e9tica provincial de M\u00e1laga<\/i> (approval: HCS-BEN-2019-01).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: APG reports personal fees and non-financial support from NOVARTIS, personal fees from ASTRA-ZENECA, personal fees and non-financial support from GSK and personal fees from TEVA. CO reports non-financial support from NOVARTIS and personal fees and non-financial support from TEVA. ALN reports personal fees and non-financial support from NOVARTIS, personal fees from ASTRA-ZENECA, personal fees and non-financial support from GSK and personal fees from TEVA.Other authors have no relevant competing interests to disclose with regard to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}